GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Buildings And Improvements

Gilead Sciences (Gilead Sciences) Buildings And Improvements

: $4,328 Mil (As of Dec. 2023)
View and export this data going back to 1992. Start your Free Trial

Gilead Sciences's quarterly buildings and improvements stayed the same from Jun. 2023 ($0 Mil) to Sep. 2023 ($0 Mil) but then increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($4,328 Mil).

Gilead Sciences's annual buildings and improvements increased from Dec. 2021 ($3,794 Mil) to Dec. 2022 ($4,390 Mil) but then declined from Dec. 2022 ($4,390 Mil) to Dec. 2023 ($4,328 Mil).


Gilead Sciences Buildings And Improvements Historical Data

The historical data trend for Gilead Sciences's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buildings And Improvements
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,358.00 3,678.00 3,794.00 4,390.00 4,328.00

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Buildings And Improvements Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,390.00 - - - 4,328.00

Gilead Sciences Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


Gilead Sciences (Gilead Sciences) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711